Multi-organ failure is a serious issue in COVID-19 due to the development of severe viral pneumonia combined with a systemic inflammatory response. Nearly 60% of individuals with pre-existing cardiovascular problems have cardiac involvement, which predicts a poor clinical outcome. Increased levels of circulating cardiac damage biomarkers and transthoracic echocardiography are used to make diagnoses during the acute phase of COVID-19. However, these tests failed to identify the mechanisms of heart damage in COVID-19 individuals. Given the possible clinical repercussions, identifying the key hallmarks of heart damage remains a critical yet unmet requirement in cardiology.
